Search

Objective:Healthcare personnel (HCP) were recruited to provide serum samples, which were tested for antibodies against Ebola or Lassa virus to evaluate for asymptomatic seroconversion.Setting:From 2014 to 2016, 4 patients with Ebola virus disease (EVD) and 1 patient with Lassa fever (LF) were treated in the Serious Communicable Diseases Unit (SCDU) at Emory University Hospital. Strict infection control and clinical biosafety practices were implemented to prevent nosocomial transmission of EVD or LF to HCP.Participants:All personnel who entered the SCDU who were required to measure their temperatures and complete a symptom questionnaire twice daily were eligible.Results:No employee developed symptomatic EVD or LF. EVD and LF antibody studies were performed on sera samples from 42 HCP. The 6 participants who had received investigational vaccination with a chimpanzee adenovirus type 3 vectored Ebola glycoprotein vaccine had high antibody titers to Ebola glycoprotein, but none had a response to Ebola nucleoprotein or VP40, or a response to LF antigens.Conclusions:Patients infected with filoviruses and arenaviruses can be managed successfully without causing occupation-related symptomatic or asymptomatic infections. Meticulous attention to infection control and clinical biosafety practices by highly motivated, trained staff is critical to the safe care of patients with an infection from a special pathogen.

Following the required review period initiated in August 2018, the Department of Health and Human Services, National Institutes of Health (NIH), published the final changes to the Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines) in April 2019. This amendment focused on the review, registration, and reporting requirements for human gene transfer studies. In addition, the Recombinant DNA Advisory Committee (RAC) was renamed the Novel and Exceptional Technology and Research Advisory Committee (NeXTRAC) to serve as an advisory body on emerging technologies.

Early 2016, investigators at Emory University challenged the Biosafety Office with the task of reviewing and guiding how research with Zika virus, an emerging infectious disease, could be conducted...

In 2008, Emory University implemented a laboratory self-inspection program where researchers were asked to complete an annual inspection of their lab spaces and report findings to the Environmental Health and Safety Office (EHSO). This article will describe how the implementation of various research safety programs has had an impact on researcher participation in the annual laboratory self-inspection program over the past four years. Results will be discussed to show that increased participation in the program is an indication of improved safety culture and the development of an educational environment that fosters self-reporting in Emory laboratories.

In the present study attempt has been made to identify the possible factor(s) which are responsible for Eales' disease. The serum of Eales' patients and that of age and sex matched healthy controls did not differ in their total protein concentration. Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) analysis did not reveal any difference between the two groups. However, analysis of the serum samples with isoelectric focusing showed the presence of two unique proteins with pI of 5.5 and 5.9 in Eales' patients. Further two dimensional SDS-PAGE analysis indicated the presence of a distinct protein spot with a pI of 5.9 and a molecular weight around 23 KD in the serum of Eales' patients. This 23 KD protein has been partially purified and found to be anionic in nature. Antisera to this partially purified protein have been raised and tested. The implication of this finding is discussed in relation to the aetiology of Eales' disease.